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Abstract
Tuberculosis (TB) is still the number one cause of death due to an infectious disease. Pharmacokinetics and pharmacodynam-
ics of anti-TB drugs are key in the optimization of TB treatment and help to prevent slow response to treatment, acquired 
drug resistance, and adverse drug effects. The aim of this review was to provide an update on the pharmacokinetics and 
pharmacodynamics of anti-TB drugs and to show how population pharmacokinetics and Bayesian dose adjustment can be 
used to optimize treatment. We cover aspects on preclinical, clinical, and population pharmacokinetics of different drugs 
used for drug-susceptible TB and multidrug-resistant TB. Moreover, we include available data to support therapeutic drug 
monitoring of these drugs and known pharmacokinetic and pharmacodynamic targets that can be used for optimization of 
therapy. We have identified a wide range of population pharmacokinetic models for first- and second-line drugs used for TB, 
which included models built on NONMEM, Pmetrics, ADAPT, MWPharm, Monolix, Phoenix, and NPEM2 software. The 
first population models were built for isoniazid and rifampicin; however, in recent years, more data have emerged for both 
new anti-TB drugs, but also for defining targets of older anti-TB drugs. Since the introduction of therapeutic drug monitor-
ing for TB over 3 decades ago, further development of therapeutic drug monitoring in TB next steps will again depend on 
academic and clinical initiatives. We recommend close collaboration between researchers and the World Health Organization 
to provide important guideline updates regarding therapeutic drug monitoring and pharmacokinetics/pharmacodynamics.
Key Points 
Information on pharmacokinetics and pharmacody-
namics of anti-tuberculosis drugs can help to optimize 
treatment.
Population pharmacokinetics and Bayesian dose adjust-
ment can help to optimize dose adjustment.
There is still a significant knowledge gap for many of the 
tuberculosis drugs.
1 Introduction
Tuberculosis (TB) is still the number one cause of death 
due to an infectious disease. The World Health Organiza-
tion estimated that about 1.6 million individuals died from 
TB in 2018. Of the 10 million people that developed TB in 
2018, 3.4% of new cases and 18% of previously treated TB 
cases were estimated to carry a drug-resistant TB strain [1]. 
Most of the new cases with drug-resistant TB were diag-
nosed with multi-drug-resistant (MDR)-TB, defined as TB 
that is resistant to at least isoniazid and rifampicin. Despite 
all current efforts, the global burden of disease is not falling 
fast enough to reach the milestones of the ‘WHO End TB 
Strategy’ [1]. Next to that, the COVID-19 pandemic will fur-
ther jeopardize TB control [2]. Providing patients with more 
active and less toxic treatment may help to achieve goals. In 
addition to the development of new drugs, optimization of 
current treatment is important to ensure that drugs for drug-
susceptible (DS) and drug-resistant TB are given at doses 
(and achieve exposures) most likely to be effective without 
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causing significant toxicity. The aim of this narrative review 
is to summarize the knowledge on the pharmacokinetics and 
pharmacodynamics of the currently available anti-TB drugs 
and show how population pharmacokinetics coupled with 
therapeutic drug monitoring (TDM) can be used to optimize 
treatment for individual patients.
2  Pharmacokinetics and Pharmacodynamics 
of Anti‑TB Drugs
Pharmacokinetics describes the behavior of a drug in the 
patient’s body, including absorption, distribution, metabo-
lism, and excretion, whereas pharmacodynamics describes 
the biochemical or pharmacological effect of a drug at the 
site of action in the patient’s body. Over the past decade, 
pharmacokinetic (PK) and pharmacodynamic (PD) science 
has greatly contributed to the understanding of TB treat-
ment response and outcome [3]. In infectious diseases, it is 
common to link exposure of the drug to the sensitivity of the 
bacteria, the minimum inhibitory concentration (MIC). In 
TB, the PK/PD indexes are similar to those for other infec-
tious diseases; maximal plasma concentration (Cmax)/MIC, 
area under the concentration–time curve of a dosing inter-
val (AUC 0–τ)/MIC, and time of the concentration over MIC 
(T > MIC). Often, the total concentration, i.e., the sum of 
the unbound and plasma protein bound fraction of the drug, 
is determined. Only the free (f) drug can diffuse through 
biological membranes to the site of infection and exert its 
pharmacological effect [4]. Therefore, especially for highly 
bound drugs, the above indexes should be converted to 
fCmax/MIC and fAUC 0–τ/MIC. For dose optimization, most 
studies aim at achieving drug exposure associated with effi-
cacy in 80% of the patients. In clinical practice, MIC deter-
minations and free drug concentrations are not measured 
because of logistical or financial limitations. In such cases, 
low exposure of a certain drug is often reported as a risk fac-
tor for suboptimal treatment. As there is no formal definition 
of ‘low concentration’, we have defined low exposure to be 
< 50% inhibitory concentration, which is the concentration 
that causes 50% of the maximum kill. This is, in our opin-
ion, more meaningful than expressing it as a percentage of 
exposure achieved in healthy volunteers because that does 
not include a measure of response.
For most drugs, specific PK/PD indexes have been linked 
to their efficacy, reflecting their time- or concentration-
dependent activity. However, it is important to note that 
Cmax and AUC 0–τ are closely linked and therefore their PK/
PD indexes as well.
Hollow fiber infection models have been very useful to 
explore PK/PD relationships as it is possible to simulate 
human concentration–time profiles, and test different dos-
ing strategies [5]. Although hollow fiber infection models 
have limitations, i.e., a lack of human immune response and 
a maximum number of drugs that can be tested simultane-
ously, the results correlate well with treatment response [6], 
which resulted in endorsement by the European Medicines 
Agency to make use of these models to guide dose selection 
for clinical trials [7].
3  Population Pharmacokinetics
The typical PK profile of a drug and the variability among 
individuals can be characterized with population PK mod-
els. Also known as nonlinear mixed-effect models, this is 
a type of compartmental model consisting of a structural 
part describing the typical behavior, and a stochastic part 
accounting for random variability [8]. The structural part 
includes the primary PK parameters such as the rate of 
absorption, volume of distribution, and clearance, as well as 
a quantitative estimate of the influence of patient characteris-
tics (covariates, e.g., body size, age, genetic polymorphisms) 
on those parameters. The stochastic part describes the mag-
nitude and distribution of random variability between indi-
viduals and within an individual between different dosing 
occasions. It also contains the unexplained variability, i.e., 
the residual error. Population PK models are developed 
using drug concentration measurements gathered after con-
trolled dosing. The development and evaluation of the popu-
lation PK models are done according to widely accepted 
standards in the field [9], generally employing software 
packages such as NONMEM (ICON plc, Gaithersburg, MD, 
USA) and Monolix (Lixoft, Antony, France). An overview 
of the set-up and development using population PK models 
is presented in Fig. 1.
4  TDM and Dose Adjustment
Therapeutic drug monitoring is a tool used to integrate PK 
and PD knowledge to optimize and personalize drug therapy. 
Therapeutic drug monitoring uses drug plasma concentra-
tions to personalize drug therapy to bring and keep the con-
centration within the targeted therapeutic range. Below this 
range, the treatment is less effective, whereas high concen-
trations may result in toxicity [4]. When selecting a popula-
tion PK model for TDM purposes, it is important to consider 
if the population in which the model was developed is repre-
sentative for the population where TDM is to be conducted.
Therapeutic drug monitoring is mostly performed using 
blood samples, i.e., serum, plasma, or dried blood spot, 
while the TB infection is located elsewhere, in the lungs or 
extra-pulmonary, for instance, in the central nervous system 
in the case of TB meningitis. Drug penetration at the site 
of mycobacterial infection may be hampered, if the disease 
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progresses and caseous lesions are formed [10]. Strydom 
et al. investigated the penetration of nine anti-TB drugs in 
resected lung tissue and showed that, irrespective of the drug 
choice, patients with cavitary disease were at risk for sub-
therapeutic concentrations [10].
Derived or secondary PK parameters commonly used in 
TDM such as AUC 0–τ, Cmax, and trough concentration (Cmin) 
can be predicted for specific individuals based on a popula-
tion PK model, relevant dosing, and covariate information 
plus any observed drug concentrations. Correct handling of 
inter-occasion variability is important to maximize the preci-
sion of the prediction [11].
For most anti-TB drugs, the AUC 0–τ (often AUC 0–24 h)/
MIC is the most predictive PK/PD index. However, a spe-
cific AUC 0–24 h/MIC target value has not yet been estab-
lished for all anti-TB drugs. Here, it must be addressed that 
individual MIC values might not always be reliable and 
often are not available early in treatment. Moreover, MIC 
values might be significantly different when using different 
methods (e.g., solid or liquid media) [5, 12, 13]. This has 
important implications for the interpretation of AUC 0–24 h/
MIC target values when taking into account how the MIC 
was determined in that study.
Obtaining a full PK curve to calculate the AUC 0–24 h using 
non-compartmental analysis techniques is a laborious and 
expensive procedure and is thus not feasible in clinical prac-
tice. A limited sampling strategy (LSS) either based on a 
population PK model or on multiple linear regression may 
help to overcome these problems. This method implies that a 
limited number, usually one to three, of appropriately timed 
blood samples is needed to adequately predict the AUC 0–24 h 
as a measure for drug exposure [14]. Population PK models 
are often used in clinical dosing software that aids in esti-
mating PK parameters such as AUC and that uses Bayesian 
simulations to estimate appropriate drug exposure [15, 16].
Bayesian-informed dosing takes into account the prior 
information (including patient-specific values of covariates 
such as body size, age, and genetics) from a population PK 
model and uses individual measurements, usually drug con-
centrations, to provide a patient-tailored posterior dosing 
recommendation. This allows individual patients plasma 
drug exposures to meet the PK/PD target [17]. The advan-
tages of the Bayesian approach are the flexible timing of 
samples, as the population PK model can correct for devia-
tions, and that it takes a number of covariates into account 
leading to a more accurate estimation of AUC 0–24 h [18]. The 
advantage of multiple linear regression-based LSSs is that 
these do not require modeling software and AUC 0–24 h can be 
easily estimated using only an equation and the measurement 
of drug concentrations. The disadvantage is that samples 
should be taken as close as possible to predefined schedules, 
and the population of interest should be comparable to the 
population in which the multiple linear regression has been 
performed because patient characteristics are not included 
in the equations to estimate drug exposure [18].
5  Anti‑TB Drugs
In the section below, we summarize the mechanism of 
action, PK/PD drivers from preclinical models, human phar-
macokinetics (with sources of variability, where known), 
and clinical PK/PD targets for each drug that is used in the 
treatment of drug-susceptible or MDR-TB. An overview on 
Fig. 1  Population pharmacokinetic (PK) modeling. incl. including, MIC minimum inhibitory concentration, PD pharmacodynamic, TDM thera-
peutic drug monitoring. Created with Biorender.com
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relevant PK models is included and recommendations on 
sampling strategies and dosing strategies are summarized. 
Table 1 gives an overview of the published population PK 
models per anti-TB drug. Table 2 indicates PK/PD targets 
and normal ranges of exposures that have been identified for 
the different drugs, this is not repeated in the text. 
We used a non-systematic literature search in PubMed 
using a combination of the following keywords: tubercu-
losis, [drug name], pharmacokinetics, pharmacodynamics, 
sampling, and concentration. Case reports, abstracts, and 
posters were excluded. Included articles were limited to 
the English language. References of included articles were 
scanned for possible relevant articles. The search was last 
performed on 4 August, 2020.
5.1  Isoniazid
5.1.1  Preclinical Pharmacokinetics/Pharmacodynamics
Isoniazid is active against Mycobacterium tuberculosis 
(MTB), inhibiting the mycolic acid synthesis, which affects 
cell wall synthesis, resulting in a bactericidal effect [19]. 
Furthermore, isoniazid has an effect on DNA biosynthesis 
and has it has been shown that early bacterial activity (EBA) 
on the first 2 days of therapy is related to the acetylator type 
and 600 mg achieves the highest EBA [19, 20]. Hollow fiber 
infection models showed that isoniazid has bactericidal 
activity that is driven by AUC 0–24 h/MIC [21, 22]. Studies in 
the mouse confirm this bactericidal activity, but isoniazid 
appears to be a weak sterilizing drug [23]. In the mouse, the 
activity of isoniazid appeared to be more concentration than 
time dependent, with Cmax/MIC and AUC 0–24 h/MIC having 
a strong association with activity [24].
5.1.2  Clinical Pharmacokinetics/Pharmacodynamics
Isoniazid is fairly hydrophilic, with moderate clinical plasma 
concentrations 2 h after ingestion (C2) of 3–6 mg/L after a 
300-mg dose, and 9–15 mg/L after a 900-mg dose [25, 26]. 
Isoniazid is unable to penetrate and accumulate in caseous 
granulomas [10]. In healthy volunteers and patients with 
TB starting on therapy, the administration of isoniazid with 
a high-fat meal modestly reduced Cmax and bioavailability 
[27, 28]. Both orange juice and aluminium–magnesium ant-
acid produced little effect on the bioavailability of isoniazid 
[27]. Isoniazid metabolism is genetically determined based 
on N-acetyl transferase 2 activity [25, 27]. It has been pro-
posed that patients be split between having none, one or two 
rapid N-acetyl transferase 2 alleles and that dosing could be 
then adapted to 2.5 (slow acetylators), 5.0, and 7.5 mg/kg 
(fast acetylators), respectively [29]. Pharmacokinetic data 
for isoniazid in adults and children with TB suggested that 
low and variable concentrations are common [30, 31]. In 
142 drug-susceptible patients with TB, Pasipanodya et al. 
showed that to achieve a favorable outcome, in order of 
importance, AUC 0–24 h of pyrazinamide, rifampicin, and 
isoniazid should be over 363, 13, and 52 mg h/L respec-
tively. Low Cmax of rifampicin (< 6.6 mg/L) and isoniazid 
(< 8.8 mg/L) preceded all (three) cases of acquired drug 
resistance [31].
5.1.3  Population Pharmacokinetics, TDM, and Dosing
Standardized doses may not be adequate for isoniazid, espe-
cially given the differences between fast and slow acetyla-
tors. Therapeutic drug monitoring could be used to rapidly 
find the correct dose for each patient [32].
Twelve population PK models were found from the time 
period of 1997–2019 (Table 1). Most of the models were 
built with NONMEM and included the acetylation status/N-
acetyl transferase 2 genotype as a covariate on clearance.
Limited sampling strategies were developed for all four 
first-line TB drugs and moxifloxacin in an ethnically heter-
ogenous population, using intensive PK sampling after the 
intake of drugs on an empty stomach and after more than 2 
weeks of therapy [33]. For isoniazid, LSSs of 1, 2.5, and 6 h 
post-dose performed best [33]. Recently, several LSSs were 
proposed for isoniazid alone or in combination with other 
first-line drugs. Limited sampling strategies were derived 
from a study with intense sampling of 20 patients conducted 
in Indonesia, who started on TB medication [34]. Both stud-
ies used the best subset selection, multiple linear regression 
to calculate LSS and the chosen LSS performed best at esti-
mating the AUC 0–24 h.
5.2  Rifampicin
5.2.1  Preclinical Pharmacokinetics/Pharmacodynamics
Rifampicin binds to and inhibits the action of the DNA-
dependent RNA polymerase of mycobacteria. It has both 
bactericidal and sterilizing activity. In the past decades, it 
was assumed that the efficacy of rifampicin is associated 
with Cmax/MIC, but recent preclinical studies have estab-
lished that the microbial killing can also be explained by 
AUC/MIC [35, 36]. Given the short half-life of rifampin of 
around 2 h at steady state, there is a high correlation between 
Cmax and AUC. Moreover, in one of these studies, it was well 
presented that in a mouse model with dose fractionation and 
ranging, the PK/PD parameter that correlated best with a 
decrease of bacterial counts was AUC/MIC [36].
5.2.2  Clinical Pharmacokinetics/Pharmacodynamics
Rifampicin is preferably taken on an empty stomach, as 
intake with food reduces Cmax and causes a modest decrease 
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in AUC 0–24 h [28, 37]. However, in the case of gastrointes-
tinal adverse effects, concomitant intake with a light meal 
is recommended to prevent or alleviate these effects. The 
distribution of rifampicin is fast and includes all fluids and 
organs, but only about 5% of rifampicin reaches the cerebro-
spinal fluid [38].
Repeated daily administration of rifampicin results in a 
decrease in exposure and half-life of the drug, owing to an 
increased rate of drug clearance caused by auto-induction 
[39]. This is separate from induction of the cytochrome 
P450 system by rifampicin (see below). Increasing the dose 
of rifampicin results in a more than proportional increase 
of exposure in plasma (non-linear pharmacokinetics). 
Rifampicin is excreted mainly through the bile. Urinary 
excretion is about 10–15% of biliary excretion but increases 
with the dose.
Rifampicin is a potent inducer of several phase I and II 
metabolic enzymes and drug transporter proteins, often 
resulting in a decrease in exposure of concomitantly used 
drugs [40]. This is especially true for cytochrome P450 3A4, 
a major drug-metabolizing pathway. Significant induction 
after starting rifampicin is reached after a few doses and is 
complete after a week [40]. Baseline enzyme activity after 
discontinuing rifampicin is attained in about 2 weeks.
The drug is currently used in a dose of 10 mg/kg daily, 
but this is at the lower end of the dose–response curve. A 
dose of 35 mg/kg daily, resulting in a ten-fold higher AUC 
0–24 h value in plasma, is safe and tolerable for 3 months 
[41, 42]. Moreover, higher dosing has shown a significant 
relationship between exposure to rifampicin and EBA [43]. 
Higher rifampicin exposures also reduce the time to culture 
conversion in pulmonary TB [44]. A meta-analysis on the 
exposure of rifampicin reported that at least 25-mg/kg dos-
ing is required to achieve PK/PD targets [45].
5.2.3  Population Pharmacokinetics, TDM, and Dosing
Nineteen population PK models for rifampicin in adult 
humans with fully re-implementable parameter values 
could be identified in the time period from 1997 up to 2018 
(Table 1). These models differed with respect to the num-
ber of compartments, the inclusion of components for non-
linearity and for auto-induction, which are both typical to 
rifampicin. Only one model was based on higher doses of 
rifampicin up to 40 mg/kg [46]. Most of the models were 
built in NONMEM.
Limited sampling strategies were developed using the 
best subset selection, multiple linear regression for all four 
first-line TB drugs and moxifloxacin in an ethnically heter-
ogenous population, using intensive PK sampling after the 
intake of drugs on an empty stomach and after more than 
2 weeks of therapy [33]. Limited sampling at various fixed 
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Table 2  PK parameters and TDM of anti-tuberculosis drugs
Drug DoseA PK/PD target for 
 efficacyB

















1, 2.5, 6 h [33]
1, 6, 8 h [34]











1, 3, 8 h [14]
2, 4 h [47]
PZA 25–35 mg/kg AUC/MIC > 
8.42 [215]




0, 2, 6 h [33]
0, 5, 8 h [34]
EMB 25 mg/kg AUC/MIC >119 
[22]
T>MIC (R) [67]
2–6 [26] E: No
T: Yes
0, 2.5, 6 h [33]
2, 4, 8 h [34]

















0, 5 h [89]
MFX 400 mg [53] fAUC/MIC > 42
fAUC/MIC > 53 
(R) [82]
35 (10–80)G













0, 1.5, 6 h [33]
0, 6 h [18]
BDQ [93, 216] 400 mg QD for 
14 days, 200 
mg TW
AUC 0–168 h/MIC 
or  Cavg/MIC 
[98]












LZD [217, 218] 600 mg fAUC/MIC: 119 
[103, 105]
Cmin < 2 mg/L 
(T) [108]
100 (107.5 ± 
30.16) [103]








0, 2 h [115]
CFZ
[121, 122]










250–750 mg T > MIC 30% 
[126]
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prediction of AUC 0–24 h of all drugs separately and simul-
taneously. The limited sampling formula called for 2-, 4-, 
and 6-h samples [33]. Another study also applied a linear 
regression approach, but focused on the prediction of the 
AUC 0–24 h of rifampicin and other TB drugs during the first 
3 days of treatment [34]. In the homogenous Indonesian pop-
ulation studied, limited sampling at 2, 4, and 8 h post-dose 
performed best to predict AUC 0–24 h values of all first-line 
TB drugs.
Sturkenboom et al. were the first to use a model-based 
(maximum a posteriori Bayesian fitting) approach to derive 
a LSS for rifampicin [14]. They extended the population 
used by Magis-Escurra et al. [33], which took rifampicin on 
an empty stomach, to patients who ingested the drug with a 
light meal and derived a population PK model in MWPharm 
AM amikacin, AUC 0–24 area under the concentration–time curve from time 0–24 h, BDQ bedaquiline, BID twice daily CFZ clofazimine, Cmax 
maximum plasma concentration, CS/TZ cyloserine/terizodone, DLM delamanid, EMB ethambutol, ERT ertapenem, ETA ethionamide, h hours, 
INH isoniazid, LFX levofloxacin, LZD linezolid, MFX moxifloxacin, MIC minimum inhibitory concentration, PAS para-aminosalicylic acid, PD 
pharmacodynamic, PK pharmacokinetic, PZA pyrazinamide, TDM therapeutic drug monitoring, R resistance, RIF rifampicin, S streptomycin, 
TW three times weekly
A Dose is once daily, unless otherwise specified
B AUC 0–24h in steady state, unless otherwise specified
C Cmax in steady state, unless otherwise specified
D LJ—Löwenstein–Jensen medium, 7H10—Middlebrook 7H10 medium, 7H11—Middlebrook 7H11 medium, MGIT—BACTEC™ Mycobacte-
rial Growth Indicator Tube™ 960, ND—not determined
E TDM indicated for E—efficacy or T—toxicity
F LSS—limited sampling strategy
G Mean (normal range)
H Median (range)
J (Selected cases) [100]
K Cmax back calculated to end of intravenous infusion [153]
L Mean ± standard deviation
M Cmax 1 h after intramuscular injection of 1 g of streptomycin [222]
Table 2  (continued)
Drug DoseA PK/PD target for 
 efficacyB

















1, 5 h [16]
AM 15–20 mg/kg 
[53]
6.5 mg/kg [155]






















1, 4 h [156]
S 12–18 mg/kg 
[53]
197 ±  26L [222] 44 (33–55)HK 
[153]








1, 6 h [222]








PAS 4000 mg fCmin > 1 mg/L 
[167]
20–60
TDM of Anti-TB Drugs
(Mediware, Zuidhorn, the Netherlands). This study showed 
that rifampin AUC 0–24 h could be predicted with acceptable 
bias and precision with optimal sampling at time points 1, 3, 
and 8 h post-dose. Furthermore, a sampling strategy using 
blood collection at convenient 2- and 4-h sampling times 
has been shown in another study to be the most suitable 
[47]. This NONMEM model was successfully implemented 
in the InsightRX (San Francisco, CA, USA) precision dos-
ing platform.
5.3  Pyrazinamide
5.3.1  Preclinical Pharmacokinetics/Pharmacodynamics
Pyrazinamide is a prodrug, which is activated to pyrazinoic 
acid inside the MTB by the bacterial pyrazinamidase [48]. 
It is mainly active against non-replicating bacilli, especially 
at low pH [49], which allows for accumulation of pyrazi-
noic acid inside the MTB [50]. In pre-clinical hollow fiber 
infection models, the sterilizing effect of pyrazinamide was 
most closely related to the AUC 0–24 h/MIC ratio [51]. The 
MIC determination is challenging, owing to the difficulty of 
reproducibly growing MTB at low pH across laboratories.
5.3.2  Clinical Pharmacokinetics/Pharmacodynamics
Pyrazinamide is used both against drug-sensitive [52] and 
resistant TB [53] and it is often dosed 20–30 mg/kg body-
weight. It should be noted that the original British Medical 
Research Council studies used fixed dosing of 1500 mg for 
patients less than 46 kg, and 2000 mg for larger patients, 
with an average dose of 35 mg/kg. A large number of PK 
studies have been published on pyrazinamide at the 20–30 
mg/kg dose: its pharmacokinetics is described by a one-com-
partment open model [54], it reaches Cmax approximately 2 
h post-dose and with a terminal half-life of approximately 
9 h it only moderately accumulates, reaching steady state 
in 2–3 days. It does not significantly bind to plasma pro-
teins [55] and it is metabolized by liver deaminase [56]. A 
recent review summarizing exposures in patients (human 
immunodeficiency virus positive/negative) reported median 
AUC 0–24 h in the range of 250–450 mg h/L and Cmax in the 
range of 25–55 mg/L [57]. Several reports indicated that 
the current weight-banded dosing approach achieves lower 
concentrations in patients with lower weight [58–61].
In clinical studies in patients with drug-susceptible TB, 
worse outcomes were observed in patients with Cmax < 35 
mg/L, while a positive association between AUC 0–24h > 
363 mg h/L and long-term TB treatment outcome has been 
reported [31, 62]. The main adverse reactions to pyrazina-
mide are arthralgia and hepatotoxicity [63]. Doses higher 
than the current doses have previously been used, and there 
is a debate regarding increasing toxicity with increasing 
doses [64].
5.3.3  Population Pharmacokinetics, TDM, and Dosing
Nine population PK models were found, from which three 
were made with NONMEM, three with Monolix, one with 
ADAPT5, and one with NPEM2 (Table 1). Only one model 
included a covariate sex on clearance [65]. Although a 
robust target for efficacy has not been established and safety 
is not of concern at the current levels, a TDM strategy could 
be useful to identify patients with low exposure using, for 
example, LSSs of 0, 2, and 6 h or 2, 4, and 8 h post-dose 
[33, 34].
5.4  Ethambutol
5.4.1  Preclinical Pharmacokinetics/Pharmacodynamics
The precise mode of action of ethambutol is not fully under-
stood, but it appears to inhibit mycobacterial cell wall arab-
ino-transferases, leading to depletion of arabinogalactan and 
lipoarabinomannan. In an early study by Dickinson et al. in 
guinea pigs, the effects of ethambutol were concentration 
dependent (Cmax/MIC) [66]. More recent experiments in the 
hollow fiber infection model showed that the microbial kill 
to ethambutol was linked to AUC 0–24 h/MIC, although in 
some experiments Cmax/MIC could also have explained the 
kill, whereas T > MIC was relevant for suppressing resist-
ance [67].
5.4.2  Clinical Pharmacokinetics/Pharmacodynamics
It often is used in a dose of 15–20 mg/kg daily, with a maxi-
mum of 25 mg/kg daily. Higher doses and exposures, espe-
cially in patients with decreased renal function, are associ-
ated with a higher incidence of retrobulbar (optic) neuritis 
[68]. The EBA of the 15–20 mg/kg dose is negligible and the 
drug has very little sterilizing activity. However, ethambutol 
is added to other first-line TB drugs during the first weeks 
of treatment to prevent rifampin resistance in cases where 
there may be unrecognized isoniazid resistance. A clinical 
trial in Indian patients with TB showed that microbiological 
response was AUC/MIC driven [69, 70].
Ethambutol can be taken with or without food, as food 
modestly reduces Cmax but does not affect the AUC 0–24 h of 
the drug [28, 37]. It has rapid good distribution throughout 
the body (including in large lung lesions), but it only pen-
etrates the cerebrospinal fluid in the presence of inflamma-
tion, probably having a minor contribution to the treatment 
of TB meningitis [71]. A recent evaluation using ultrafiltra-
tion showed an average protein binding of 12% [55]. Etham-
butol is largely excreted unchanged by the kidneys. Patients 
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with a creatinine clearance less than 30 mL/min are at risk 
for accumulation of the drug and resulting retrobulbar neuri-
tis. They should receive a longer interval between doses with 
three times a week administration of the same 15–20 mg/kg 
dose. In persons with good renal function, ethambutol shows 
a biphasic decline in plasma concentration with a terminal 
half-life of about 10–12 h. The drug shows no relevant drug 
interactions, apart from a reduction in its Cmax caused by 
aluminum-containing antacids [72].
5.4.3  Population Pharmacokinetics, TDM, and Dosing
Traditionally, limited sampling of ethambutol aimed at 
‘catching’ and estimating the Cmax of the drug in an indi-
vidual by sampling at 2 and 6 h after dosing. Recently devel-
oped LSSs aim to predict the AUC 0–24 h for ethambutol as 
well. As described earlier, Magis-Escurra et al. developed 
an LSS using best subset selection, multiple linear regres-
sion for all first-line TB drugs (including ethambutol) sepa-
rately and simultaneously [33]. Saktiawati et al. also applied 
a linear regression approach, but focused on prediction of 
the AUC 0–24 h of first-line TB drugs during the first 3 days 
of treatment, based on data from Indonesian patients with 
TB [34]. Horita et al. were the only investigators to use a 
Bayesian approach to estimate AUC 0–24 h of ethambutol in 
children [30].
Ten population PK models for ethambutol could be iden-
tified (Table 1) [30, 72–79]. These models differ with respect 
to the number of compartments, the inclusion of a lag time, 
or transit compartment absorption. Most of the models were 
built in NONMEM. It is important to note that a decreased 
renal function may be the most relevant indication for TDM 
of ethambutol, but relatively few patients with renal dys-
function were included in the various cohorts. This means 
that the effect of this covariate on clearance has not been 
adequately evaluated in population PK models. Similarly, 
only one model was derived in obese patients taking eth-
ambutol [75].
5.5  Levofloxacin/Moxifloxacin
5.5.1  Preclinical Pharmacokinetics/Pharmacodynamics
Fluoroquinolones are amongst the most potent drugs against 
MTB. They produce their rapid killing effect by inhibiting 
the bacterial DNA replication and transcription through 
affecting the type II topoisomerases [80].
The efficacy of fluoroquinolones is correlated with the 
ratio of the fAUC 0–24 h/MIC [81–83]. In addition, an 800-mg 
daily dose for moxifloxacin is suggested to achieve maximal 
kill and suppress resistance [84, 85].
5.5.2  Population Pharmacokinetics, TDM, and Dosing
Therapeutic drug monitoring of moxifloxacin and levofloxa-
cin is proposed because of high PK variability and a sub-
stantial proportion of patients showing low drug exposure 
[86–88]. Fluoroquinolones are well tolerated and adverse 
effects do not require TDM (e.g., QT interval prolongation 
by moxifloxacin). Therapeutic drug monitoring is helpful 
to ensure adequate exposure after dose adjustments of levo-
floxacin due to kidney failure or in the case of drug–drug 
interactions. For instance, moxifloxacin exposure is approxi-
mately 25% decreased if concomitantly used with rifampicin 
owing to an increase of moxifloxacin clearance [18]. Four 
population PK models were identified for levofloxacin and 
six for moxifloxacin (Table 1). The models were made 
with NONMEM, MWPharm, NPEM2, and Monolix and 
the majority were one-compartment models. To reduce the 
burden and costs of TDM, LSSs can be applied. The under 
the concentration–time curve from time 0 to 24 h can be 
adequately estimated using a population PK model and two 
optimally timed samples for levofloxacin (0 and 5 h) and for 
moxifloxacin (0 and 6 h, either with or without rifampicin) 
[18, 89].
5.6  Bedaquiline
5.6.1  Preclinical Pharmacokinetics/Pharmacodynamics
Bedaquiline is a diarylquinoline that targets mycobacterial 
ATP synthase, disrupting the bacteria’s energy metabolism 
[90]. Dose-fractionation experiments in mice identified 
AUC/MIC as the main driver of bactericidal effect [91].
5.6.2  Clinical Pharmacokinetics/Pharmacodynamics
The standard dosing regimen in the treatment of MDR-TB 
consists of a 2-week loading phase with 400 mg daily fol-
lowed by 22 weeks with 200 mg dosed three times per week. 
An alternative dosing regimen with 200 mg daily during the 
first 8 weeks, thereafter 100 mg daily, has been utilized in 
recent clinical trials [92]. Uptake of bedaquiline is increased 
when given together with food and maximal concentrations 
are expected 4–6 h after dosing. The binding to plasma pro-
teins is very high, more than 99.9%, and the distribution to 
tissues is extensive, resulting in an extremely long termi-
nal half-life [93]. One case report showed undetectably low 
bedaquiline concentrations in cerebrospinal fluid [94].
Bedaquiline is mainly hepatically cleared. Cytochrome 
P450 3A4 (primarily) transforms bedaquiline into the 
N-monodesmethyl metabolite M2, which in turn is metabo-
lized in the same way to M3 [93, 95].
A model-based PK/PD analysis of phase II data found a 
weekly average concentration (analogous to weekly AUC) 
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to be the best driver and estimated that a concentration of 
1.42 mg/L would give half of the maximal possible effect 
[96]. The relationship has also been confirmed in a separate 
study [97]. With the standard regimen typical (mean ± one 
standard deviation) maximal, average, and trough concen-
trations at day 14 are 1.6–3.2 mg/L, 0.96–2.1 mg/L, and 
0.44–1.4 mg/L, respectively [98]. At the end of the con-
tinuation phase, the corresponding values are 0.9–2.1 mg/L, 
0.41–1.2 mg/L, and 0.26–0.91 mg/L [98].
5.6.3  Pharmacokinetics, TDM, and Dosing
There are two published population PK models of bedaqui-
line in patients with drug-resistant pulmonary TB, partly 
based on the same data and both developed in NONMEM 
(Table 1). The first only describes bedaquiline [99], while 
the second also incorporates the main metabolite M2 [98]. 
There are no published evaluations of TDM sampling strate-
gies for bedaquiline. The time on treatment needs to be con-
sidered, accounting for the loading phase and the accumula-
tion. Assessing the Cmin at the end of the loading phase is a 
practically feasible option. A retrospective study described 
potential risk factors of low and high bedaquiline concentra-
tions, where administration of food, drug–drug interactions, 
gastrointestinal complaints, lower body weight, and age > 
70 years were among the named factors [100]. In addition, 
black race has been connected to approximately 50% clear-
ance [99]. Therapeutic drug monitoring could be of benefit 
for specific patients using bedaquiline; however, standard-
ized drug susceptibility testing must first be developed [101]. 
The M2 metabolite is the main driver of side effects such as 
QT prolongation and phospholipidosis [102].
5.7  Linezolid
5.7.1  Preclinical Pharmacokinetics/Pharmacodynamics
Linezolid exerts its antibacterial effect by binding 70S ribo-
somal components and disrupting the initiation of protein 
synthesis. A hollow fiber infection model study has indicated 
optimal mycobacterial kill to be associated with fAUC 0–24 h/
MIC [103]. In murine models, its sterilizing activity is dose 
related and can occur within 2 months of effective combi-
nation therapy, leading some investigators to consider short 
high-dose therapy followed by discontinuation or intermit-
tent dosing to retain efficacy whilst reducing toxicity [104, 
105].
5.7.2  Clinical Pharmacokinetics/Pharmacodynamics
The bioavailability after oral administration of linezolid 
is nearly 100%, and it shows good tissue penetration into 
tuberculous lung cavities caseating granulomas and cerebro-
spinal fluid [10, 106]. The standard adult dose (600 mg twice 
daily) is associated with myelosuppression, lactic acidosis, 
and neurotoxicity during long-term use. Consequently, a 
dose of 600 mg, or occasionally 300 mg, once daily is often 
recommended for patients with TB [104, 107].
The PK/PD target for myelotoxicity is suggested as a 
Cmin of 2 mg/L [108]. While meta-analyses and simulations 
from some of these data indicate high attainment of putative 
efficacy targets at 600 mg once or twice daily, Cmin regu-
larly exceeds the toxicity threshold with twice-daily dos-
ing [109, 110]. One study reported that higher plasma lin-
ezolid exposure and greater toxicity risk are associated with 
advancing age and lower weight [111]. It has been reported 
that 300 mg twice daily might be effective [104]. Studies 
looking into 300-mg daily dosing have shown promising 
results in some patients [112, 113]; however, until larger 
trials show results, 600 mg has been suggested to keep the 
balance between efficacy and toxicity [105]. No association 
between human immunodeficiency virus or concurrent anti-
retroviral therapy and linezolid exposure has been described 
[111]. An approach of short-duration higher dose linezolid 
to maximize efficacy whilst avoiding toxicities associated 
with cumulative dose requires further evaluation; however, 
an interim analysis of the Nix-TB trial showed a significant 
amount of patients experiencing linezolid toxicity [114].
5.7.3  Population Pharmacokinetics, TDM, and Dosing
The narrow therapeutic window has prompted suggestion 
that TDM might be beneficial. An LSS consisting of 0 and 
2 h has been described to predict the plasma AUC 0–24 h with 
acceptable bias and precision [115]. Three population PK 
linezolid models were identified (Table 1), which were all 
one-compartment models and two were developed with 
MWPharm and one with NONMEM.
5.8  Clofazimine
5.8.1  Preclinical Pharmacokinetics/Pharmacodynamics
Studies in the mouse model show that clofazimine did not 
have EBA, but subsequently demonstrated potent, dose- 
and concentration-independent bactericidal activity [116]. 
The authors suggested that much lower doses could be used 
effectively for TB and that clofazimine exhibits slow elimi-
nation [116]. In another mouse model, the activity of clo-
fazimine was confirmed to be best when administered with 
other first-line anti-TB drugs [117].
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5.8.2  Clinical Pharmacokinetics/Pharmacodynamics
Most clinical studies have used 100-mg daily doses, thus 
the literature lacks human dose-ranging data for TB. Very 
limited PK/PD data are available for clofazimine, with most 
only available as meeting abstracts.
Clofazimine is highly lipophilic, leading to high accu-
mulation in fat tissues and relatively low serum concentra-
tions (0.7–1.0 mg/L) [118]. Clofazimine is unable to pen-
etrate and accumulate in caseous granulomas, but it does 
accumulate in the highly cellular peripheral zone of the 
granuloma, consisting of macrophages, epithelioid mac-
rophages, and lymphocytes [118]. In healthy volunteers, 
the administration of clofazimine with a high-fat meal pro-
vided the greatest bioavailability. However, bioavailability 
was associated with high inter- and intra-subject variabil-
ity. Both orange juice and an aluminum-magnesium ant-
acid reduced a mean bioavailability of clofazimine [119].
5.8.3  Population Pharmacokinetics, TDM, and Dosing
Overall, three NONMEM population PK models were 
identified (Table 1). A recent population PK model on 
NONMEM described clofazimine disposition being 
strongly affected by body fat, thus clofazimine showed 
lower plasma concentrations in women [120]. Addition-
ally, it was suggested that patients with extreme body 
composition might need to have individualized dosing and 
a high-fat content might require longer loading periods 
[120]. As mentioned, specific PK/PD targets for clofazi-
mine are scarce. Clofazimine is suggested to be sampled 
2–3 h after the dose and 6 h to assess delayed absorption, 
whereas Cmax is expected at 0.5–2.0 mg/L [26, 121, 122].
5.9  Cycloserine/Terizidone
5.9.1  Preclinical Pharmacokinetics/Pharmacodynamics
Cycloserine is an amino-acid derivative, which suppresses 
the growth of MTB by inhibiting the enzymes that produce 
peptidoglycan causing changes in the cell wall [123]. Ter-
izodone contains two cycloserine molecules. Hollow fiber 
infection models have proposed that T > MIC predicts 
efficacy best [124–126].
5.9.2  Clinical Pharmacokinetics/Pharmacodynamics
Cycloserine has been suggested to be used in patients with 
rifampicin-resistant TB as a Group B drug. It may also 
be of value in the therapy of TB meningitis owing to its 
penetration into cerebrospinal fluid [126].
As cycloserine has a long half-life, different Cmax ranges 
have been reported. To determine exposure, the first meas-
urement should be done after 3–4 days of therapy and Cmax 
is expected to be around 20–35 mg/L [26, 127, 128].
5.9.3  Population Pharmacokinetics, TDM, and Dosing
Two population PK models have used the preclinical estab-
lished PK/PK index T > MIC over 30% model [125, 129]. 
Five cycloserine/terizidone population PK models were 
identified and all of these were one-compartment models 
made with different software, Monolix, NONMEM, and 
MWPharm (Table 1). Recently, a sampling strategy using 
blood collection at a convenient 4 h has been proposed in 
combination with a population PK model to estimate AUC 
0–24h obtaining a low relative error [125].
5.10  Delamanid
5.10.1  Preclinical
Delamanid is a nitroimidazole antibiotic with mechanisms 
of action including inhibition of mycolic acid synthesis and 
generation of nitrous oxide in anaerobic conditions [130]. In 
animal models, the activity of delamanid activity appears to 
be time dependent [130].
5.10.2  Clinical Pharmacokinetics/Pharmacodynamics
The licensed dose is 100 mg twice daily, for 24 weeks, but 
an alternative dosing regimen of 100 mg twice daily for 8 
weeks followed by 200 mg once daily for 16 weeks was 
used in the recent phase III trial [131]. The main route of 
metabolism of delamanid is purported to be via albumin, 
with cytochrome P450 3A playing a minor role [132]. It has 
several metabolites, but DM-6705 circulates at the highest 
concentrations. Delamanid and DM-6705 have half-lives 
of 30–38 h and 121–425 h, respectively, and the latter is 
linked to the key, albeit modest, adverse effect of delama-
nid—prolongation of the cardiac QT interval [133]. The 
bioavailability of delamanid is enhanced two- to four-fold 
by food, exposures are less than dose proportional, the drug 
is highly protein bound (> 99.5%), and the Tmax is at 4 h 
[134, 135]. This drug appears to reach high concentrations 
in the brain; its utility in central nervous system TB is being 
explored [136]. Delamanid is not an inducer or inhibitor 
of cytochrome P450 enzymes, and drug–drug interaction 
liability is low. In human EBA studies, doses of 200–300 mg 
total daily dose produced higher microbiologic activity than 
100 mg per day [134]; in a phase II trial, there was a trend 
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towards better activity of delamanid 200 mg twice daily 
compared with 100 mg twice daily on solid medium [137].
5.10.3  Population Pharmacokinetics, TDM, and Dosing
Median delamanid AUC 0–24 h after 56 days of dosing is 7.9 
mg h/L (coefficient of variation 37.5%). Maximum plasma 
concentration values are 0.4 mg/L (coefficient of variation 
40.5%) at 56 days [132, 136]. There are no clear target con-
centrations owing to a lack of clinical PK/PD data. It has 
been reported that delamanid acquires resistance quickly, 
thus optimization of therapy using TDM may help in reduc-
ing the acquired resistance [138].
5.11  Pretomanid
5.11.1  Preclinical
Pretomanid was introduced with the BPal regimen (bedaqui-
line and pretomanid with linezolid). An in vivo model pre-
sented activity comparable to isoniazid, where the suggested 
reasoning was lower bioavailability in necrotic lung granu-
lomas [139]. In another mouse model, the addition of preto-
manid showed bactericidal activity increase while prevent-
ing emergence of resistance to bedaquiline and duration of 
therapy [140]. Later, a synergistic three-drug combination, 
including pretomanid, was suggested in a time kill assay 
combined with population modeling [141].
5.11.2  Clinical Pharmacokinetics/Pharmacodynamics
Pretomanid has shown to have higher bioavailability when 
taken with food [142]. In healthy adults it has been shown 
that AUC and Cmax could be almost doubled [142]. Moreo-
ver, drug interactions have been described with rifampicin, 
lopinavir/ritonavir, and efavirenz—all of these reduce the 
AUC of pretomanid [143].
5.11.3  Population Pharmacokinetics, TDM, and Dosing
Two population PK models were identified, one in NON-
MEM and the other developed on GNU MCSim modeling 
and simulation suite (Table 1).
5.12  Meropenem/Imipenem‑Cilastatin/Ertapenem
5.12.1  Preclinical Pharmacokinetics/Pharmacodynamics
Meropenem, a carbapenem, is a member of the β-lactam 
class of antibiotics. It inhibits cell wall synthesis 
through inhibition of classical D, D-transpeptidases, and 
non-classical L, D transpeptidases [144]. Clavulanate (not 
available except co-formulated with amoxicillin) irrevers-
ibly inhibits MTB β-lactamase, potentiating the activity 
of meropenem. Ertapenem has shown to a have sterilizing 
effect against M. tuberculosis in a hollow fiber infection 
model; however, falsely high MIC values might have been 
reported because of ertapenem degradation in acidic condi-
tions, which could have led to underuse of ertapenem in TB 
therapy [145, 146].
5.12.2  Clinical Pharmacokinetics/Pharmacodynamics
In an EBA study, meropenem given at a dose of 2 g three 
times daily intravenously (supplemented with twice-daily 
amoxicillin/clavulanate) produced measurable activity in 
patients with pulmonary TB [147]. Recently presented EBA 
dose-finding trial results suggest that there is a significant 
drop in microbiologic activity when the meropenem dose is 
reduced from 6 g per day (given as 2 g three times daily) to 
3 g per day (with 1 g three times daily performing modestly 
better than 3 g once daily). Meropenem, together with amox-
icillin-clavulanate, is used off-label for TB. Doses for other 
bacterial infections range from 1.5 to 6 g per day, given in 
divided doses to maximize the activity of this time-depend-
ent drug. Most (around 70%) of an intravenous meropenem 
dose is excreted unchanged in the urine [148]. Protein bind-
ing is very low (2%). Ertapenem in a dose of 1 g once daily 
intramuscularly in combination with amoxicillin-clavulanic 
acid showed no EBA [149]. The lack of activity of this dose 
is in line with an earlier published study using the hollow 
fiber infection model indicating that a dose of at least 2 g 
once daily was required [146].
5.12.3  Population Pharmacokinetics, TDM, and Dosing
Mean meropenem AUC 0–24 h given at 2 g three times daily 
is 573 mg h/L, with a Cmax of 133 mg/L; at that dose, with 
an MIC of 1 mg/L, T > MIC is appropriately 75% [134]. In 
the absence of a PK target that maximizes efficacy against 
slow-growing MTB, it seems reasonable to strive for these 
average PK values. Collecting samples for the PK pre-dose 
and mid-dosing interval is most informative. While carbap-
enems are generally well tolerated, there is an increased 
risk of neurotoxicity with Cmin > 16 mg/L (and the dose-
limiting toxicity is chiefly diarrhea from the amoxicillin–cla-
vulanate). Therapeutic drug monitoring of meropenem in 
TB could thus serve to help with individualized dosing of 
meropenem, achieving exposures similar to those seen with 
maximal EBA activity and avoiding toxic Cmin.
Ertapenem in a 2000-mg once-daily pharmacokinetic 
exploratory study showed that f40% of T > MIC was reached 
for most patients [150]. A PK model based on data from 
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patients with MDR-TB proposed a limited sampling strategy 
of 1 h and 5 h [16].
5.13  Amikacin/Streptomycin
5.13.1  Preclinical Pharmacokinetics/Pharmacodynamics
In a hollow fiber infection model for TB, the local amikacin 
Cmax/MIC ratio of 10 was determined to be the effective PK/
PD index, closely followed by AUC/MIC [151, 152].
5.13.2  Clinical Pharmacokinetics/Pharmacodynamics
Aminoglycoside use is limited by both the parenteral 
administration and significant toxicity that is observed after 
prolonged use [153] and should only be used if drug sus-
ceptibility testing results confirm susceptibility and audi-
ometry monitoring can be ensured [53]. A 10% probability 
of ototoxicity occurred with a threshold cumulative AUC 
> 87 g h/L [154]. It has been revealed that the probability 
of ototoxicity increased sharply starting after 6 months of 
amikacin therapy to near maximum at 9 months. Consider-
ing the poor penetration of aminoglycosides in lung tissue, 
this translates into a serum Cmax/MIC ratio of 70–90 or an 
AUC 0–24 h/MIC ratio of 103 [151].
5.13.3  Population Pharmacokinetics, TDM, and Dosing
Therapeutic drug monitoring of aminoglycosides is indi-
cated to ensure efficacy and should be combined with deter-
mination of MIC as the risk of ototoxicity can be reduced if 
the MIC is low enough to lower the (cumulative) dose and 
exposure [155]. A one-compartment population PK model 
has been reported for amikacin. This included a LSS of 1 h 
and 4 h suggested for predicting AUC 0–24 h [156].
5.14  Ethionamide/Prothionamide
5.14.1  Preclinical Pharmacokinetics/Pharmacodynamics
The thiomides ethionamide and its propyl-analog prothiona-
mide are drugs with bactericidal activity against MTB [157]. 
They are considered interchangeable within anti-tubercular 
regimens [158]. In hollow fiber systems, the target exposure 
was identified as AUC 0–24 h/MIC [159].
5.14.2  Clinical Pharmacokinetics/Pharmacodynamics
It is currently used for MDR-TB at 15–20 mg/kg daily 
(maximum 1000 mg) [53] and for drug-susceptible TB in 
children or TB meningitis. The plasma protein binding of 
ethionamide is approximately 30% [160] and it is metabo-
lized by hepatic monooxygenases [161].
5.14.3  Population Pharmacokinetics, TDM, and Dosing
Three population PK ethionamide models were identified, 
from which all were one-compartment models using NON-
MEM and Pmetrics software (Table 1). Clinically, after 
administration of 250–500 mg of ethionamide, a Cmax in 
the range of 1–5 mg/L has been suggested [26]. A TDM 
strategy could identify patients with low concentrations by 
evaluating two samples at 2 h and 6 h with a Cmax of 1–5 
mg/L [26, 162, 163].
5.15  P‑Aminosalicylic Acid
5.15.1  Preclinical Pharmacokinetics/Pharmacodynamics
The mechanism of action of P-amino salicylic acid (PAS) 
remains unknown but it is assumed that it interferes with 
bacterial folate synthesis [164].
5.15.2  Clinical Pharmacokinetics/Pharmacodynamics
Although one study described a bactericidal effect of PAS at 
high (20 g) once-daily dosing [165], it is generally regarded 
as a bacteriostatic agent. It is associated with considerable 
gastrointestinal intolerance and was quickly replaced by 
isoniazid, rifampicin, and pyrazinamide in first-line anti-
TB therapy. It has recently been downgraded in the World 
Health Organization MDR-TB guidelines but retains a role 
as component of treatment for patients with extensively drug 
resistant TB (XDR-TB) and limited other options [53]. Cur-
rent PAS dosing for adults is 150 mg/kg/day in two to four 
divided oral doses (usually 8–12 g/day), and 200–300 mg/
kg/day in two to four divided doses for children. Absorption 
is improved by consumption with acidic food or yoghurt 
[166]. It attains its maximum serum concentration within 
about 2 h, and has a fairly short half-life [165]. Protein 
binding is between 50 and 60% [167]. Current granular for-
mulations are designed to provide slow release, assuming 
a fCmin > 1 mg/L will be maintained [167]. Some authors 
have reported that a high Cmax may be more important for 
prevention of resistance to partner drugs [168].
5.15.3  Population Pharmacokinetics, TDM, and Dosing
Three NONMEM population PK models were identified, 
which were all one-compartment models (Table 1). A role 
for TDM in PAS dosing has not yet been explored.
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6  Concluding Remarks
In this review, over 80 different population PK models for 
14 anti-TB drugs are presented.
As different models are difficult to compare and because 
the true model cannot be identified, there is no such thing 
as the ‘best’ or most recommended model. This was already 
stated in 1976, in one of the most famous adages in pharma-
cokinetics: ‘all models are wrong, some are useful’ [169]. 
Our personal preference would be using a validated model 
and performing TDM with Bayesian estimation to most 
accurately estimate AUC for the individual patient and situ-
ation. This can be done using different modeling and Bayes-
ian simulation software. A good overview of different avail-
able methods has recently been presented [170].
By including TDM as an opportunity for optimizing TB 
treatment in TB guidelines [53, 171, 172], the first step 
towards implementation of precision medicine has been 
made. The guidelines include indications and clinical con-
ditions for which TDM may be useful. To be of practical use, 
guidance is required on how drug exposure should be evalu-
ated and how dosages could be adjusted [173]. We therefore 
performed this review evaluating the available literature on 
pharmacokinetics and PK modeling of anti-TB drugs. For 
the first-line anti-TB drugs, it is clear that studies focussed 
mainly on rifampicin and isoniazid [25, 174–176]. Phar-
macokinetic variability is substantial and can be explained 
by pharmacogenetic differences and other factors such as 
co-morbidities [45, 177, 178]. With respect to dose opti-
mization, there is a clear rationale based on in vitro PK/PD 
and clinical studies. Unfortunately, a well-designed study 
comparing TDM with standard of care is lacking. Although 
higher dosages are currently being trailed for rifampicin, 
TDM will likely still have a role as PK variability is still 
high, which leads to the conclusion that a high dose does 
not automatically result in a high exposure in every patient.
For anti-TB drugs used for the treatment of M/XDR-TB, 
there is a significant knowledge gap for many of the drugs. 
Only for the fluoroquinolones, linezolid, and aminoglyco-
sides does a substantial body of evidence support TDM. The 
new drugs such as bedaquiline, delamanid, and pretomanid 
lack this abundance of data but publications on acquired 
resistance, drug–drug interactions, and significant variability 
of bioavailability based on concomitant food intake already 
provide a rationale that TDM may be of use for the newer 
drugs as well. However, it needs to be mentioned again that 
a well-designed prospective study comparing TDM in M/
XDR-TB is still lacking. As researchers, we ourselves often 
struggle with conducting prospective studies to show the 
value of TDM. Recently, a review by Märtson et al. identi-
fied knowledge gaps and provided guidance with an appro-
priate checklist and data elements that are suggested to take 
into account when designing and conducting high-quality 
TDM studies in the field of infectious diseases [179]. Briefly, 
the focus was on estimating drug exposure and assessing 
the susceptibility of the pathogen, but also suggestions on 
how to select study endpoints and clinical trial design were 
provided [179].
Logistical issues regarding TDM samples seem to be a 
hurdle that will be overcome in the next couple of years 
owing to the introduction of dried blood spot monitoring, 
point of care saliva tests, and urine testing [173, 180]. To 
support a physician in making informed dosing decisions in 
individual patients, easy-to-use model-informed precision 
dosing software has to be made freely accessible via mobile 
platforms such as smartphones and tablets. On-site patient 
covariates and drug concentrations can be used to simulate 
dosing regimens to maximize the likelihood to attain the 
therapeutic target. Such software is currently under develop-
ment for drugs such as vancomycin but there is a clear need 
to expand the panel with anti-TB drugs.
As TB treatment duration is long, there is an urgent need 
to find biomarkers that predict clinical outcome. A combina-
tion of dose optimization based on measured drug concentra-
tion and pathogen susceptibility with a sensitive and respon-
sive biomarker would be helpful to optimize treatment.
Since the introduction of TDM for TB over 3 decades 
ago, further development of TDM in TB next steps will 
again depend on academic and clinical initiatives sup-
ported by funding institutions such as EDCTP or the Bill & 
Melinda Gates Foundation, as the pharmaceutical industry is 
not interested in personalized prescribing for the novel com-
pounds and the generic pharmaceutical industry has no role 
in drug development or treatment optimization. We recom-
mend that researchers work closely together with guideline 
issuing bodies like the World Health Organization to ensure 
the evidence generated will be reviewed during guideline 
updates. With such an approach, TDM will become avail-
able within the next 5 years and can help to contribute to 
END TB.
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